Compare IDEXX Laboratories, Inc. (IDXX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Union Pacific Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $543.91 (market cap $43.58B), while Union Pacific Corporation trades at $291.79 (market cap $174.04B). The key difference: Union Pacific Corporation is far larger — about 4× IDEXX Laboratories, Inc.'s market cap, and Union Pacific Corporation pays a 1.88% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | UNP | |
|---|---|---|
Market Cap | $43.58B | $174.04B |
Sector | Health | Industrials |
52-Week High | $766.68 | $301.75 |
52-Week Low | $526.44 | $214.91 |
Enterprise Value | $44.48B | $204.51B |
Dividend Yield | — | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Union Pacific (UNP) trades at $293.13, down 2.86% on the day, with technical indicators showing a bullish trend but overbought RSI levels. The company maintains strong profitability with a 29.2% net margin and 40.69% ROE, supported by consistent cash flow from operations of $9.29B in 2025. Recent news highlights Q2 2026 earnings anticipation and progress on the proposed Norfolk Southern merger, while a class action lawsuit presents a legal overhang.
Outlook remains positive with analyst consensus pointing to 6% upside to a $311.07 price target, though regulatory hurdles for the merger and economic sensitivity pose risks. The stock offers a solid dividend yield and operational resilience, but investors should weigh earnings performance against valuation multiples above industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
